Your browser doesn't support javascript.
loading
Community Consensus Guidelines to Support FAIR Data Standards in Clinical Research Studies in Primary Mitochondrial Disease.
Karaa, Amel; MacMullen, Laura E; Campbell, John C; Christodoulou, John; Cohen, Bruce H; Klopstock, Thomas; Koga, Yasutoshi; Lamperti, Costanza; van Maanen, Rob; McFarland, Robert; Parikh, Sumit; Rahman, Shamima; Scaglia, Fernando; Sherman, Alexander V; Yeske, Philip; Falk, Marni J.
Afiliación
  • Karaa A; Department of Genetics, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • MacMullen LE; Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Campbell JC; Minovia Therapeutics, Cambridge, MA 02138, USA.
  • Christodoulou J; Murdoch Children's Research Institute and Department of Paediatrics, University of Melbourne, Melbourne, Victoria 3052, Australia.
  • Cohen BH; Department of Pediatrics and the Rebecca D. Considine Research Institute, Akron Children's Hospital, Akron, OH 44308, USA.
  • Klopstock T; Friedrich-Baur Institute, Department of Neurology, University Hospital, LMU, Munich 80336, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich 80336, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich 80336, Germany; German Network for Mitochondrial Disorders (mitoNET),
  • Koga Y; Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume 830-0011, Japan.
  • Lamperti C; UO Genetics and Neurogenetics, Fondazione IRCCS Instituto Neurologico C. Besta, Milan 20126, Italy.
  • van Maanen R; Khondrion BV., Nijmegen 6525 EX, The Netherlands.
  • McFarland R; WCMR Newcastle University, Newcastle NE1 7RU, UK.
  • Parikh S; Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
  • Rahman S; UCL Great Ormond Street Institute of Child Health and Great Ormond, Street Hospital for Children NHS Foundation Trust, London WC1N 1EH, UK.
  • Scaglia F; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children's Hospital, Houston, TX 77030, USA; Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, Hong Kong SAR NT, China.
  • Sherman AV; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Yeske P; United Mitochondrial Disease Foundation, Pittsburgh, PA 15239, USA.
  • Falk MJ; Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Adv Genet (Hoboken) ; 3(1)2022 Mar.
Article en En | MEDLINE | ID: mdl-35317023
ABSTRACT
Primary mitochondrial diseases (PMD) are genetic disorders with extensive clinical and molecular heterogeneity where therapeutic development efforts have faced multiple challenges. Clinical trial design, outcome measure selection, lack of reliable biomarkers, and deficiencies in long-term natural history data sets remain substantial challenges in the increasingly active PMD therapeutic development space. Developing "FAIR" (findable, accessible, interoperable, reusable) data standards to make data sharable and building a more transparent community data sharing paradigm to access clinical research metadata are the first steps to address these challenges. This collaborative community effort describes the current landscape of PMD clinical research data resources available for sharing, obstacles, and opportunities, including ways to incentivize and encourage data sharing among diverse stakeholders. This work highlights the importance of, and challenges to, developing a unified system that enables clinical research structured data sharing and supports harmonized data deposition standards across clinical consortia and research groups. The goal of these efforts is to improve the efficiency and effectiveness of drug development and improve understanding of the natural history of PMD. This initiative aims to maximize the benefit for PMD patients, research, industry, and other stakeholders while acknowledging challenges related to differing needs and international policies on data privacy, security, management, and oversight.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Adv Genet (Hoboken) Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Adv Genet (Hoboken) Año: 2022 Tipo del documento: Article